Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol

doi:10.1002/ehf2.14577

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 醫務管理系(所) > 期刊論文 > Item 310902800/34893

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34893

標題:	Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol
作者:	Lee, Wei-Chieh Lin, Yu-Wen Shih, Jhih-Yuan Chen, Zhih-Cherng Wu, Nan-Chun Chang, Wei-Ting
貢獻者:	Natl Sun Yat Sen Univ, Coll Med, Sch Med Chi Mei Med Ctr, Dept Internal Med, Div Cardiol Natl Cheng Kung Univ, Coll Med, Inst Clin Med Chi Mei Med Ctr, Dept Surg, Div Cardiovasc Surg Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Natl Sun Yat Sen Univ, Sch Med Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis Chi Mei Med Ctr, Div Cardiovasc Med
關鍵字:	Apoptosis Atrial fibrillation Carvedilol Ivabradine Mitral regurgitation
日期:	2024
上傳時間:	2024-12-25 11:05:12 (UTC+8)
出版者:	WILEY PERIODICALS, INC
摘要:	Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta-blockers. Degenerative mitral regurgitation (MR) is a valvular heart disease often associated with the development of HF and atrial fibrillation (AF). However, studies comparing the effects of ivabradine and beta-blockers on MR are lacking. Therefore, this study aimed to explore the potential therapeutic effects of ivabradine and carvedilol on MR using a rat model.Methods and results Using a novel echo-guided mini-invasive surgery, MR was created in 12-weeks-old Sprague-Dawley rats. After 2 weeks, the rats were randomized to receive either ivabradine or carvedilol for 4 weeks. Echocardiography was performed at baseline and at two-week intervals. Following haemodynamic studies, postmortem tissues were analysed. Notably, the MR-induced myocardial dysfunction did not improve considerably after treatment with ivabradine or carvedilol. However, in haemodynamic studies, pharmacological therapies, particularly carvedilol, mitigated MR-induced chamber dilatation (end-systolic volume and end-diastolic volume; MR vs. MR + Carvedilol; P < 0.05) and decreased compliance (end-systolic pressure-volume relationship; MR vs. MR + Carvedilol; P < 0.05). Compared with ivabradine, a shorter duration (MR vs. MR + Carvedilol; P < 0.05) and reduced inducibility (MR vs. MR + Carvedilol and MR vs. MR + Ivabradine; P < 0.05) of AF were observed in MR rats treated with carvedilol. Similarly, reduced cardiac fibrosis and apoptosis were observed in the MR rat model in the treatment groups, especially in those treated with carvedilol (MR vs. MR + Carvedilol; P < 0.01).Conclusions Although both ivabradine and carvedilol, at least in part, mitigated MR-induced chamber dilatation and decreased compliance, carvedilol had a better effect on reversing MR-induced cardiac fibrosis, apoptosis, and arrhythmogenesis than ivabradine. When compared with Ivabradine, MR rats treated with carvedilol exhibited a shorter duration and reduced inducibility of AF, thus providing more effective suppression of HCN4. Further investigations are required to validate our findings.
關聯:	Esc Heart Failure, v.11, n.1, pp.251-260
显示于类别:	[醫務管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
ehf2.14577.pdf		2396Kb	Adobe PDF	12	检视/开启
index.html		0Kb	HTML	38	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....